Unlike rival CDK 4/6 inhibitor abemaciclib, patients don't need to be lymph-node positive to receive ribociclib after surgery ...

Targeted Oncology provides news, videos, and reviews on the rapidly evolving world of targeted therapies and immunotherapy ...

4 Study participants were randomized to receive 400 mg ribociclib combined with nonsteroidal aromatase inhibitors (NSAIs) or NSAIs alone. 1 The suggested dose in an adjuvant treatment setting with ...

The US FDA has approved Kisqali (ribociclib) for treating early-stage breast cancer in combination with hormone therapy. It ...

The team found adding ribociclib, a drug that belongs to a class of CDK4/6 inhibitors, to standard hormone therapy not only ...

Ad hoc announcement pursuant to Art. 53 LR Broad indication in HR+/HER2- stage II and III early breast cancer (EBC) at high risk of recurrence approximately doubles population eligible for CDK4/6 ...

A drug called ribociclib, currently used to treat breast cancer, could slow the progression of certain pediatric high-grade gliomas, an aggressive type of childhood brain cancer, a new study has ...

Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window The FDA on Tuesday approved ribociclib (Kisqali) in combination with endocrine therapy as adjuvant treatment for early ...

Basel: Novartis has announced that the US Food and Drug Administration (FDA) has approved Kisqali (ribociclib) in combination ...

Novartis’ Kisqali receives US FDA approval to reduce risk of recurrence in people with HR+/HER2- early breast cancer: Basel Thursday, September 19, 2024, 13:00 Hrs [IST] Novarti ...